EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudie

Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas

Haonan Yu, Xiangyuan Bao, Yian Gu, Meijie Pan, Qing He, Dong Li, Qiusong Chen, Shaobo Yao iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07288-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Haonan Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China. Hauptthemen laut MEDLINE: Exenatide, Fluorodeoxyglucose F18, Insulinoma, Organometallic Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Joint Funds for the Innovation of Science and Technology, Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Accurate preoperative localization is particularly important for surgical treatment of insulinomas. Current imaging methods, including 18F-FDG (FDG) PET/CT, 68Ga-DOTATATE (TATE) PET/CT, CE-CT, and CE-MRI, have limitations. This prospective study provides a direct comparison of 68Ga-NOTA-Exendin-4 (Ex4) PET/CT with other imaging techniques. METHOD: 47 patients with biochemically proven endogenous hyperinsulinemic hypoglycemia underwent Ex4 PET/CT and other imaging methods. Sensitivity and accuracy of all imaging procedures for localizing insulinoma were calculated at the patient level and lesion level. Both clinical (>10 years experience) and junior (< 2 years experience) nuclear medicine physician readings were used to assess the diagnostic efficacy. We compared the SUVmax and tumor-to-background ratio (TBR) of three tracers and analyzed the values with Ki-67, maximum tumor diameter, and glucose metabolism indicators. RESULTS: In patient level, the sensitivity and accuracy of Ex4 PET/CT (94.11% and 95.74%) were higher than TATE PET/CT (70.59%, p = 0.026; 78.72%, p = 0.030), FDG PET/CT (50.00%, p < 0.001; 63.83%, p < 0.001), CE-CT (77.77%, p = 0.135; 72.22%, p = 0.007), and CE-MRI (63.64%, p = 0.135; 43.75%, p < 0.001), respectively. Interobserver agreement was higher for Ex4 PET/CT than TATE PET/CT and FDG PET/CT (Cohen κ, 0.839 vs. 0.707 and 0.784, respectively). SUVmax and TBR of Ex4 and TATE PET/CT were significantly higher than FDG PET/CT (p < 0.01). Negative correlations of tumor Ki-67 with TATE PET/CT were observed with SUVmax (r = -0.637, p < 0.001). SUVmax and TBR of three molecular imaging methods had positive correlations with the maximum tumor diameter (p < 0.05), except TBR of FDG PET/CT. Semi-quantitative values of the three tracers showed no correlation with the lowest blood glucose level, corresponding insulin, and C-peptide level. TBR of TATE PET/CT showed a positive correlation with C-peptide (r = 0.393, p = 0.043). CONCLUSION: Ex4 PET/CT showed superior characteristics in localization compared to routine imaging modalities in benign insulinomas. Ex4 PET/CT demonstrates better imaging quality and interpretability than FDG PET/CT and TATE PET/CT. Combined Ex4 and TATE PET/CT could provide a comprehensive evaluation/localization of insulinoma. TRIAL REGISTRATION: The trial was retrospectively registered at ClinitalTrial.gov (NCT06690957 and NCT06725693) on November 14, 2024 and December 5, 2024.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExenatideFluorodeoxyglucose F18InsulinomaOrganometallic CompoundsPancreatic NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle Aged

Stichwörter der Autor:innen

Diagnostic performanceGLP-1 receptorInsulinomaPET/CT

Substanzen

ExenatideFluorodeoxyglucose F18gallium Ga 68 dotatateOrganometallic Compounds

Autor:innen und Institutionen

  • Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China.
  • The Clinical Research and Translational Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian Province, China.
  • Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, 300052, China.
  • Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China. dr_lidong@163.com.
  • Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China. qs_c8@hotmail.com.
  • Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China. yaoshaobo008@163.com.

ORCID-Profile: Shaobo Yao

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Fujian Province
  • Joint Funds for the Innovation of Science and Technology, Fujian Province

Zitieren

APA

Yu, H., Bao, X., Gu, Y., Pan, M., He, Q., Li, D., Chen, Q., & Yao, S. (2025). Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07288-x

Vancouver

Yu H, Bao X, Gu Y, Pan M, He Q, Li D, et al. Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07288-x

BibTeX
@article{Yu2025,
  author = {Yu, Haonan and Bao, Xiangyuan and Gu, Yian and Pan, Meijie and He, Qing and Li, Dong and Chen, Qiusong and Yao, Shaobo},
  title = {Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07288-x}
}
Kostenlos starten →